Tuberculosis preventive therapy (TPT) is crucial for eliminating TB globally, especially for children at risk. Barriers and solutions in the TB infection care cascade need to be addressed for successful implementation of TPT.

Bedaquiline and delamanid are new and effective drugs against resistant tuberculosis (TB) with optimal efficacy in adults. However, further studies are needed to confirm their safety and efficacy in the pediatric population.

The number of tuberculosis cases has decreased over the past 10 years in Britain, but the disease still poses a significant risk. The success of treatment depends on proper prescription, patient compliance, and supervision by experienced physicians.

Mortality in people with HIV and COVID-19 is associated with suboptimal HIV control and comorbidities. Vaccination and proper management of HIV and comorbidities are crucial for reducing mortality.

Pneumothorax is a significant cause of morbidity and mortality in India. The study found that secondary spontaneous pneumothorax is more common than primary, with pulmonary tuberculosis being the leading cause.

Advancements in adult tuberculosis research have deepened our understanding of host susceptibility and resistance mechanisms, as well as the effects of HIV infection on TB transmission. Multidrug-resistant disease is a global health problem.

The World Health Organization has released new guidelines for the management of latent tuberculosis infection (LTBI). The guidelines recommend systematic testing and treatment for certain high-risk groups, including people living with HIV and patients receiving certain types of treatment. Viral replication is a strong risk factor for TB progression, and targeted testing and treatment based on viral replication status could be more efficient than testing all HIV-infected patients.

High mortality rates during the first year of antiretroviral therapy (ART) in resource-limited settings emphasize the need for earlier HIV diagnosis and initiation of ART. Strategies to address this burden should include screening and prophylaxis for opportunistic infections, optimized management of specific diseases and treatment complications, and program strengthening.

Advances in TB diagnosis and treatment in children include more effective tests, improved sampling methods, and paediatric-friendly drug dosing. However, research on drug-resistant TB in children is still ongoing. Adequate funding and effective national TB programs are crucial in achieving the goal of ending the TB epidemic.

A study in Estonia found that 5% of patients with active tuberculosis had extensively drug-resistant disease, with risk factors including previous treatment, HIV infection, homelessness, and alcohol abuse. Targeting these factors could aid tuberculosis control efforts.

There is a growing association between communicable and non-communicable diseases in low- and high-income countries. Reducing these diseases requires implementing specific treatments for each disease while recognizing the interactions and benefits of overlapping treatments.

Treatment of latent tuberculosis infection (LTBI) is important for tuberculosis control, but poor adherence to treatment regimens is a major limitation. A study comparing 4 months of rifampin therapy with 9 months of isoniazid therapy found that rifampin had fewer adverse effects and better treatment completion rates, highlighting its potential as an alternative treatment for LTBI.

The text discusses the potential benefits of using Bacillus Calmette-Guerin (BCG) vaccination as a preventive and therapeutic approach for asthma. Studies have shown that BCG vaccination can improve lung function and reduce medication use in asthmatic patients, particularly in young women. The vaccination may work by inducing immune responses and promoting regulatory T cell development, which helps suppress asthma symptoms.